ImageneBio Inc
NASDAQ:IMABiotechnology
Healthcare
$4.61 +6.06%
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
52W Low $3.94High $18.00
Volume 0.00M
Average 0.35M
Income Statement
Follow revenue through to earnings.
Revenue
$800,000.00
FY 2025 · Annual
-77.1% YoYOperating Income
-$48.45M
FY 2025 · Annual
Net Income
-$45.35M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.99M | 15.62M | 9.16M | 3.5M | 800K |
| Cost of Revenue | 47.11M | 64.32M | 1.02M | 1.53M | 1.03M |
| Gross Profit | (16.12M) | (48.7M) | 8.14M | 3.5M | (233K) |
| Gross Margin | -52.0% | -311.8% | 88.9% | 100.0% | -29.1% |
| Research & Development | 47.11M | 64.32M | 59.65M | 32.11M | 28.53M |
| Selling, General & Admin | 18.02M | 22.2M | 24.93M | 8.39M | 20.73M |
| Operating Expenses | 18.02M | 22.2M | 83.56M | 40.5M | 48.22M |
| Depreciation & Amortization | 544K | 751K | 1.02M | 1.53M | 1.03M |
| EBITDA | (33.57M) | (68.01M) | (67.31M) | (35.03M) | (44.67M) |
| EBITDA Margin | -108.3% | -435.5% | -734.8% | -1000.8% | -5583.3% |
| Operating Income | (34.14M) | (70.9M) | (75.42M) | (37M) | (48.45M) |
| Operating Margin | -110.2% | -454.0% | -823.3% | -1057.1% | -6056.4% |
| Interest Income | 23K | 2.15M | 7.11M | 7.37M | 2.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 23K | 2.14M | 7.09M | 445K | 2.75M |
| Income Before Tax | (34.12M) | (68.77M) | (68.33M) | (36.56M) | (45.7M) |
| Pre-Tax Margin | -110.1% | -440.3% | -745.9% | -1044.4% | -5712.4% |
| Income Tax Expense | 0 | 0 | (162K) | 13K | (350K) |
| Net Income | (34.12M) | (68.77M) | (68.17M) | (36.57M) | (45.35M) |
| Net Margin | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (Basic) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| EPS (Diluted) | (0.95) | (1.90) | (1.63) | (1.02) | (10.76) |
| 35.98M | 36.19M | 41.74M | 48.26M | 4.87M | |
| 35.98M | 36.19M | 41.74M | 48.26M | 4.87M |
IMA Earnings Waterfall · TTM
NASDAQ:IMA · Revenue to Net Income
Key Ratios
EPS$-4.64
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-18.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$45.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.64, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| EFFECT | EFFECT filing | Aug 11, 2026 | |
| EFFECT | EFFECT filing | Aug 11, 2026 |
How much revenue does IMA generate?
ImageneBio Inc (IMA) reported $800,000.00 of revenue in fiscal 2025.
Is IMA profitable?
ImageneBio Inc (IMA) reported -$45.35M of net income, with a net margin of -5668.6%.
Continue the stock analysis
Jump to another research area for this company.